Heart failure drug withdrawal trial aims to free patients from lifelong pills

NCT ID NCT06128980

Recruiting now Disease control Sponsor: Herlev and Gentofte Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether heart failure patients who fully recover after treatment for a fast heart rhythm (like atrial fibrillation) can safely stop their heart failure medications. 348 participants will be randomly assigned to either gradually stop their drugs or continue them as usual. The goal is to see if stopping drugs is as good as continuing them at preventing heart failure from coming back, while reducing side effects and costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sequential weaning of heart failure medications (SGLT2i, MRA, BB, ACEi/ARB/ARNi)
What this could lead to: If successful, this could allow many heart failure patients who recover after treating a fast heart rhythm to safely stop some or all of their heart failure drugs, reducing side effects and medication burden.
What could go wrong: This is a Phase 2/3 trial with 348 patients, so results are not yet proven. There is a risk that stopping medications could lead to heart failure relapse, and the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial flutter cardiac rhythm disease heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH REDUCED EJECTION FRACTION HEART RHYTHM DISORDER

Contacts and locations

Locations

Herlev-Gentofte Hospital
RECRUITING

Copenhagen, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.